Sorrento Therapeutics Inc (SRNE)

[dia76ca]

The March 2022 presentation outlines the 5 minute,near PCR sensitivity VIREX tests(slide 19)
DIAGNOSTIC PIPELINE
• Virex Health, Inc. is a Boston, Massachusetts company that has developed a powerful,
broadly applicable at-home diagnostic platform (“Virex Technology”).
• Virex Technology, invented and developed by Boston University (BU) Professors Mark
Grinstaff and Scott Schaus and Virex scientists, employs widely used electrochemistry
found in household diabetes glucometer devices for next generation diagnostics.
• Virex Technology has demonstrated extremely high sensitivity for multiple biological
analytes including COVID-19 virus detection as sensitive as 10 TCID50, rivalling PCR
sensitivity.
• Virex’s early liver cancer biomarker test detects a liver cancer biomarker in as little as
5 microliters of blood.
• Virex’s diagnostic tests provide qualitative and/or quantitative results in as little as 5
minutes.
• Virex’s diagnostic tests leverage existing worldwide manufacturing infrastructure for glucometers and glucose strip tests to provide affordable and highly scalable next-generation diagnostic solutions for COVID-19 tests, early cancer detection and beyond.